• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    test company saurabh

    Almac Group

    Adare Pharma Solutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    test company saurabh

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Possibly Time for a New Paradigm

    Or, why the chicken should cross the road

    Possibly Time for a New Paradigm
    Related CONTENT
    • ACG Launches ACG Laboratories
    • CDMO Cognate BioServices Teams Up with L7 Informatics
    • Asymchem
    • Life Science Success Podcast: Matt Hicks
    • A Potential “Marriage”
    Emil W. Ciurczak, DoraMaxx Consulting10.10.18
    For decades, the approach to crushing “blockbuster drugs” from the “grapes” of research departments was to get bigger: hire more scientists, build more labs, and spend much more money. The cycle began roughly in the 1970s when some blockbusters (e.g., Valium) came on the scene. Unfortunately, much like licking chapped lips, while blockbusters—drugs with more than a billion dollar yearly sales—felt good, they were, in reality (I hate myself for this pun), gateway drugs. What I mean by that is, while they felt good, and companies spent large chunks of the income on discovering the next best blockbuster, the size of the companies grew nearly exponentially. This growth, voluntary at first, became necessary. The mere size of these “new, super-sized” companies demanded further growth, which then demanded more and more blockbusters to keep them alive and growing.

    The size of many companies became so complex, they were almost unmanageable. Clearly, one managerial path is to delegate when one is overwhelmed with tasks. A company is somewhat like a skilled juggler: it can suspend a growing number of balls in the air, BUT there are limits! Let us examine two reasons to outsource production of, what we call, “product X.”

    1. The product is a steady seller—$10-$50,000,000 per annum—but there is only a need to produce several batches per year/quarter. Under cGMP (batch) process production, the time involved in setting up, breaking down, cleaning, and validating the cleanliness of the process equipment, makes the product, still profitable, less attractive (i.e., profitable). Two obvious reasons are: when the equipment (and operators) are tied up with product X, they cannot be utilized on products Y, Z, A-F, slowing down output of blockbuster; and when a smaller, dedicated contract manufacturing organization (CMO) could make the product without the higher overhead of the parent company, it allows for both higher profit margins and better-timed deliveries to customers.
    2.  Product X is the blockbuster and it is tying up most of the process equipment, blocking production of products A ->F, Y, and Z. While the pipeline of X is satisfied, all the others could be delayed to market, causing shortages and, potentially, doctors switching their patients to competitors’ products. Once switched, they are fain to return.

    Ok, these may well be convincing reasons for outsourcing either the blockbuster or the “second tier” products, but there are a number of roadblocks, real or imagined, to any or all outsourcing scenarios. Some are quite real and potentially serious, while some are mere convenience issues.

    Different quality
    “Different” quality is an issue due to different equipment, personnel and their levels of training and experience, and quality of excipients/APIs.

    Even following an MMF (Master Manufacturing Formula) to the letter, we have found via NIRS that different equipment has a different “process signature.” That is, it has, for example, slight variances in pressure across the face of a tablet punch, different speed, ejection types, etc. All show up in a NIR spectrum, should process control be performed in that fashion.

    Different suppliers of raw materials, especially in other continents, will have slightly different qualities, causing slight variations in final product performance. Clearly, it would be prohibitively expensive to ship U.S.-made materials to, say, Vietnam for use, so we use locally-produced materials.

    There are a number of unscrupulous producers. Should a CMO/CRO/CCO decide to use OOS materials (non-GMP). This could cause either or both a recall or heath/stability problems.

    Supply chain length
    Every added step between the raw materials and final customer adds the potential of delay. With the current tariff wars, the lower cost of outsourcing to another country could be offset by added tariffs. Add to that, shipping and weather delays, labor disputes, and border checks for proper documentation, and the added time makes any profit advantage evaporate.

    Analytical ability of “CxO”
    While a “name” pharma company will have invested millions to build, equip, and staff modern analytical/QC laboratories, the vast majority of contract companies do not have the resources to keep abreast of new and improved analytical hardware and software. This disparity slows transfer of production from the originator company to the outsourcing site.

    Technology transfer
    When we speak of technology transfer, we mean both process equipment and measurement technology.

    In terms of processing hardware, this would include blenders, granulators, drying apparatus and tableting machines, especially for specialty dosage forms—osmotic pumps.

    For laboratory/process monitoring instrumentation, these can be simple upgrades to totally innovative technologies. The most common analytical technologies (i.e., ultraviolet/visible and mid-range infrared spectroscopies) are almost always available and lab models can be used to build models for process analyses. However, most contract manufacturing locations do not have the experience in sampling and calibrating for process analyses.

    A simple, yet significant upgrade would be a shift from HPLC (high performance liquid chromatography) to UPLC (where U = ultra) for small and large molecule analyses, both for R&D and QC applications. Extending this upgrade to a process is somewhat easier than a non-contact method.

    More complex technologies (i.e., Near-Infrared, TeraHertz, Raman), which exist in both lab and process-monitoring forms, are nowhere near being common or addressed in most university curricula. Larger companies, mainly due to a larger staff, can afford to allow on-the-job training for their analysts; small CxO’s need, but can seldom afford, an analyst who can hit the ground running.

    Some suggested solutions
    Starting with the analytical components of outsourcing, there are a number of potential fixes. Based on what was done at one company for whom I worked, merely transfer the proper analytical instrument along with the product to be controlled. When we developed a new drug product analysis via GC or HPLC, we sent the unit, along with appropriate columns and, sometimes, solvents to the QC department in lieu of expecting them to purchase, set-up, and perform IQ/OQ/PQ on unfamiliar equipment.

    This approach may be modified with special or unfamiliar hardware (i.e. NIRS or Raman), where the equipment is purchased and qualified by the client company and one or more analysts from the contract manufacturer are trained either in-house or at the client’s facility before it is sent to the contract facility. This assures parallel analyses at both locations at a cost of less than $100,000 per unit. This is usually far less that the contract company attempting the job on its own.

    For processing equipment, sending classic, production-sized units—blenders, fluid-bed units, etc.—is getting much costlier, unless we are speaking about smaller, less expensive, more versatile continuous manufacturing equipment. If the former, then, unless it is a specialty unit, the contract company will likely both have and know how to operate it.

    Again, any differences between the contract company’s equipment or experience can be made smoother by cooperative training and hardware exchange.

    Novelty processing and monitoring equipment, such as 3-D printers and on-line monitors (i.e., NIR or TeraHertz), are becoming more and more common in larger companies. It would behoove the client/parent company to invest some time and money in order to bring the contract facility on par with the originator’s plant/lab.

    When you, the client company, start to become confident with a new analytical or process technology, including software for process control, an eye should be cast towards eventually cloning your success at one or more contract organization sites. While they can also use these technologies for other clients, the fact that they will more quickly finish the orders for others, assures that the equipment will be more readily available for your tasks.

    Also, the more the contract facility’s staff uses the new equipment, the more skilled they become and the better they can make your product.

    The true bottom line for all these changes and updates to contract facilities is that the owner of the blockbuster or other product would have the options not available previously. Management can either allot the multi-batch per week product or the batch or two per quarter product to the contract organization with confidence.

    As far as CROs are concerned, cloning the technologies makes sense, even if your chief researchers are not present to run all the tests/experiments. The protocols may be developed by the home lab personnel and carried out by the contract team. With the internet secured by a cloud, one would assume, the experiments’ progress may be followed remotely, making visits to the contracted site less frequently needed.

    The same could apply to clinical contract organizations. They need not be geographically very close, since their lab facilities would be cloned for the client and their goods made and packaged under identical conditions to the client’s. This would also allow easy oversight via the internet.

    So, it seems that several technical trends are concomitantly occurring with the current trend of Big Pharma downsizing/outsourcing.

    For one, real-time, in-process monitoring and control, a.k.a., PAT, where the old-fashioned concept of one-size-fits-all master manufacturing formulas (MMFs) is becoming a quaint relic of the past. With the advent of PAT/QbD, companies now “blend until blended,” not to a pre-set time. They dry until dry, etc., not to a time point. This allows CMOs to more closely mimic the originators’ product, giving them more confidence with outsourcing.

    Also, continuous manufacturing obviates the need for legions of trained analysts at contract organizations, lowering the time and cost of technology transfer.

    In short, technology improvements seem to be willing to help companies outsource many of their functions with confidence. We’re living the dream.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • merck
    • quality
    • apis
    • Development
    Suggested For You
    ACG Launches ACG Laboratories ACG Launches ACG Laboratories
    CDMO Cognate BioServices Teams Up with L7 Informatics CDMO Cognate BioServices Teams Up with L7 Informatics
    Asymchem Asymchem
    Life Science Success Podcast: Matt Hicks Life Science Success Podcast: Matt Hicks
    A Potential “Marriage” A Potential “Marriage”
    Vetio Animal Health Vetio Animal Health
    An “All-You-Can-Eat” Buffet for Excellence An “All-You-Can-Eat” Buffet for Excellence
    The Times, They Are a-Changin’ The Times, They Are a-Changin’
    Technological Arms Race Could Improve Bio Process Mfg. Efficiency Technological Arms Race Could Improve Bio Process Mfg. Efficiency
    Kura Oncology Appoints COO, Clinical Development VPs Kura Oncology Appoints COO, Clinical Development VPs
    The Final Frontier The Final Frontier
    We Need to Get Back to Basics We Need to Get Back to Basics
    AMAG Pharma Appoints EVP AMAG Pharma Appoints EVP

    Related Columns

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19


    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18

    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18


    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18

    • Chemistry | Laboratory Testing
      When Your Product is Neither a Liquid or a Solid

      When Your Product is Neither a Liquid or a Solid

      And you need to analyze/control it, in real time.
      Emil W. Ciurczak, DoraMaxx Consulting 01.30.18


    • Analytical Services
      Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17

    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17

    • Analytical Services
      Quality Risk Management

      Quality Risk Management

      It’s not just for the big guys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 04.03.17


    • Analytical Services | R&D
      Trends in Pharma Analysis

      Trends in Pharma Analysis

      A look at how pharma analysis technology continues to evolve to meet market needs
      Emil W. Ciurczak, DoraMaxx Consulting 03.07.17

    • Analytical Services | Drug Development | Laboratory Testing

      Orphan Drug Development & Production: Turning Lemons into Lemonade

      Forming a “win-win-win” paradigm for large pharma companies, contract service providers and generics
      Emil W. Ciurczak, DoraMaxx Consulting 01.26.17

    • Analytical Services | Bioanalytical Services | Chemistry | Laboratory Testing

      Hyperspectral Imaging

      It’s not just for the Big Boys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 11.09.16

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers
    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Coatings World

    Latest Breaking News From Coatings World

    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Inahsi Naturals Achieves EU Compliance
    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Happi

    Latest Breaking News From Happi

    Sephora To Open More Stores in 2021
    Clean Beauty Collective Supports EarthDay.org
    Freckle Pens Are Spot On!
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UFlex adds capacity in packaging films
    CEC expands into labels and packaging with Heidelberg
    ABG delivers Digicon Series 3 to UK printer
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login